Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

The NBA Hall of Famer joined forces with the telehealth platform to restart his weight loss journey and raise awareness about ...

But so far, most researchers are reassured as are regulators in the UK, United States and Europe.”Prof Sattar and Dr Cork have unpacked the side effects to be aware of:BlindnessStomach issues‘Ozempic ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Hims & Hers Health Inc (HIMS) reports a 111% revenue surge and outlines future growth strategies amid expanding service ...

25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

They’ve all been used to describe effects of the rapid weight loss that can come from taking glucagon-like peptide-1 receptor agonists like semaglutide ... you rapidly lose underlying body ...